Research and Development Investment: GSK plc vs Alkermes plc

A Decade of R&D Investment: GSK plc vs Alkermes plc

In the ever-evolving pharmaceutical industry, research and development (R&D) investments are crucial for innovation and growth. Over the past decade, GSK plc and Alkermes plc have demonstrated contrasting strategies in their R&D expenditures. From 2014 to 2023, GSK consistently invested heavily, with a peak in 2023, where their R&D expenses reached approximately 6.2 billion USD, marking a 44% increase from 2014. In contrast, Alkermes plc showed a more volatile pattern, with a significant spike in 2022, where their R&D expenses surged to nearly 394 million USD, a staggering 50-fold increase from 2014. This divergence highlights GSK's steady commitment to innovation, while Alkermes' strategy appears more opportunistic, possibly reflecting shifts in their research focus or financial strategy. As the pharmaceutical landscape continues to change, these investment patterns offer insights into each company's future trajectory.